. 2023 Oct 17;15(10):2480. doi: 10.3390/pharmaceutics15102480

Table 4.

Summary of tri-modal synergistic PDT/PTT/chemotherapy by nanomedicines responsive to TME stimuli.

PS	Photothermal Agent	Chemotherapeutic Drug	TME Involved	Entities Responsive to TME	Purpose	Tumor Model In Vivo	Reference
BPNs	BPN/MnO₂	DOX	High level of H₂O₂, low pH	MnO₂	Oxygen generation for hypoxia relief and PDT enhancement, controlled drug release	Mice with HeLa tumors	[82]
aza-BODIPY	aza-BODIPY	DOX	High level of H₂O₂, low pH	MnO₂	Hypoxia relief and drug release	/	[83]
PCN-224(Mn)	PDA	Iniparib	High level of H₂O₂	Mn-TCPP	Hypoxia relief, drug release and PDT enhancement	BALB/c nude mice with MDA-MB-231 tumors	[84]
Ce6	PDPC micelles	PDOX	Low pH	PEG-b-PDPA	Controlled drug release	Nude mice with MCF-7/ADR tumors	[85]
MoSe₂	Bi₂Se₃/MoSe₂	DOX	Low pH	Bi-M-3@PEG-Dox	Controlled drug release	Mice with U14 tumors	[86]
IR820	IR820	DTX	Low pH	CaCO₃	Controlled drug release	PC-3 xenograft tumor-bearing nude mice	[87]
TCPP	AuNS	GA	Low pH	ZrTCPP	Controlled drug release	BALB/c mice with 4T1 tumors	[88]
PpIX	GNRs	DOX	Low pH	MPH	Controlled drug release	BALB/c nude mice with MCF-7 tumors	[89]
IR820	IR820	DOX	GSH and HAase	HA and organosilica	Controlled drug release	Nude mice with 4T1 tumors	[90]
IR825	IR825	RESV	ROS	MND-IR@RESV	Enhanced cellular uptake	Nude mice with U14 tumors	[91]
ICG	PDA	TPZ	Low pH	CaCO₃	Controlled drug release	Mice with U87MG tumors	[36]